Yu-Jia Gao1, Yan Xin, Jian-Jun Zhang, Jin Zhou. 1. The Fourth Laboratory of Cancer Institute & Department of Tumor Pathology of General Surgery Institute, The First Affiliated Hospital of China Medical University, Shengyang, Liaoning Province, China.
Abstract
AIM: To investigate the aberrant methylation of CHFR promoter in human gastric cancer (GC) and its impact on the expression of CHFR mRNA and protein, as well as its correlation with clinical and histological features of human GC. METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to detect the methylation status of CHFR promoter in 20 primary GC samples and paired normal gastric mucosa. The CHFR mRNA and protein expressions were investigated both by RT-PCR and by Western blotting. The CHFR protein expression in 39 GC samples was immunohistochemically examined. RESULTS: The DNA methylation of the CHFR gene was found in 9 of the 20 GC samples (45%) and the down-regulation of CHFR mRNA and protein was significantly associated with the methylation status of the CHFR gene (P = 0.006). In 20 samples of corresponding non-neoplastic mucosa, no DNA methylation of the CHFR gene was detected. The CHFR gene methylation in poorly differentiated GC samples was significantly higher than that in well-differentiated GC samples (P = 0.014). Moreover, the negative CHFR protein expression rate in paraffin-embedded GC samples was 55.07% (38/69), the positive rate in poorly differentiated GC samples was 36.73% (18/49), which was significantly lower than 65.00% (13/20) in well-differentiated GC samples (c2 = 4.586, P = 0.032). CONCLUSION: Aberrant methylation of the CHFR gene may be involved in the carcinogenesis and development of GC, and is the predominant cause of down-regulation or loss of CHFR mRNA or protein expression. As aberrant methylation of CHFR promoter is correlated with tumor differentiation, it may help to predict the prognosis of GC and CHFR may become a novel target of gene therapy for GC in the future.
AIM: To investigate the aberrant methylation of CHFR promoter in humangastric cancer (GC) and its impact on the expression of CHFR mRNA and protein, as well as its correlation with clinical and histological features of human GC. METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to detect the methylation status of CHFR promoter in 20 primary GC samples and paired normal gastric mucosa. The CHFR mRNA and protein expressions were investigated both by RT-PCR and by Western blotting. The CHFR protein expression in 39 GC samples was immunohistochemically examined. RESULTS: The DNA methylation of the CHFR gene was found in 9 of the 20 GC samples (45%) and the down-regulation of CHFR mRNA and protein was significantly associated with the methylation status of the CHFR gene (P = 0.006). In 20 samples of corresponding non-neoplastic mucosa, no DNA methylation of the CHFR gene was detected. The CHFR gene methylation in poorly differentiated GC samples was significantly higher than that in well-differentiated GC samples (P = 0.014). Moreover, the negative CHFR protein expression rate in paraffin-embedded GC samples was 55.07% (38/69), the positive rate in poorly differentiated GC samples was 36.73% (18/49), which was significantly lower than 65.00% (13/20) in well-differentiated GC samples (c2 = 4.586, P = 0.032). CONCLUSION: Aberrant methylation of the CHFR gene may be involved in the carcinogenesis and development of GC, and is the predominant cause of down-regulation or loss of CHFR mRNA or protein expression. As aberrant methylation of CHFR promoter is correlated with tumor differentiation, it may help to predict the prognosis of GC and CHFR may become a novel target of gene therapy for GC in the future.
Authors: Richard J Shaw; Gillian L Hall; Derek Lowe; Triantafillos Liloglou; John K Field; Phillip Sloan; Janet M Risk Journal: Arch Otolaryngol Head Neck Surg Date: 2008-03
Authors: Myoung Sook Kim; Cinthia Lebron; Jatin K Nagpal; Young Kwang Chae; Xiaofei Chang; Yiping Huang; Tony Chuang; Keishi Yamashita; Barry Trink; Edward A Ratovitski; Joseph A Califano; David Sidransky Journal: Biochem Biophys Res Commun Date: 2008-03-17 Impact factor: 3.575
Authors: Jan Harder; Oliver G Opitz; Jan Brabender; Manfred Olschewski; Hubert E Blum; Shuji Nomoto; Henning Usadel Journal: Int J Cancer Date: 2008-06-15 Impact factor: 7.396
Authors: Yazhuo Li; Yunsheng Yang; Youyong Lu; James G Herman; Malcolm V Brock; Po Zhao; Mingzhou Guo Journal: Gastric Cancer Date: 2014-04-21 Impact factor: 7.370